Fluidigm Announces Fourth Quarter and Full Year 2018 Financial Results Fourth quarter revenue increased 17 percent to $32.3 million Mass cytometry revenue growth of 48 percent in fourth quarter Full year 2018 revenue increased 11 percent to $113.0 millionIncluding...

Caprion Biosciences Offers Mass Cytometry CRO Services to Advance Biomarker Discovery and Immune Monitoring SOUTH SAN FRANCISCO, Calif. and MONTREAL, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Caprion Biosciences, a world-leading specialty contract research organization (CRO) laboratory providing state-of-the-art...

Foundational 10,000 Immunomes Project Uses Mass Cytometry to Establish a Reference Standard for the Human Immune System Providing the largest source of standardized, multi-omic immune data from healthy human subjects to accelerate translational research SOUTH SAN FRANCISCO, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) --...

Fluidigm Announces Conference Call and Webcast of Third Quarter 2018 Financial Results SOUTH SAN FRANCISCO, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), a leader in mass cytometry and microfluidics technologies, announced today that it will report...

Fluidigm Announces Co-Marketing Agreement with Visiopharm to Expand and Simplify Imaging Mass Cytometry Data Analysis SOUTH SAN FRANCISCO, Calif., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) and Visiopharm A/S today announced a co-marketing relationship to automate image analysis for...